Ebola vaccine trials fast-tracked by international consortium
28 August 2014 | By GlaxoSmithKline
Unprecedented international consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine...
List view / Grid view
News
Pfizer’s investigational vaccine candidate for Clostridium difficile receives U.S. Food and Drug Administration Fast Track designation
28 August 2014 | By Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to the company’s investigational Clostridium difficile vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C...
Amgen announces positive top-line results from Phase 3 YUKAWA-2 trial of evolocumab
28 August 2014 | By Amgen
...in combination with statins in Japanese patients with high cardiovascular risk and high cholesterol.
Pfizer and Merck to collaborate on study evaluating novel anti-cancer combination regimen
27 August 2014 | By Pfizer
Pfizer Inc. and Merck & Co. Inc. through a subsidiary, announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib (XALKORI®) with Merck’s investigational anti-PD-1 antibody pembrolizumab...
European Commission approves Bristol-Myers Squibb’s Daklinza (daclatasvir) across multiple genotypes for the treatment of chronic hepatitis C infection
27 August 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults...
Novo Nordisk buys production plant in New Hampshire
27 August 2014 | By Novo Nordisk
Novo Nordisk announced the acquisition of a manufacturing facility in West Lebanon, New Hampshire, USA, from Olympus Biotech...
GSK receives FDA approval of an additional Promacta® (eltrombopag) indication for use in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST)
27 August 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the once-daily use of Promacta® (eltrombopag) in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy...
Tecan and RECIPE announce co-marketing agreement for automation of LC-MSMS IVD kits
26 August 2014 | By kdm communications
With clinical laboratories increasingly turning to high throughput LC-MSMS analysis, laboratory automation specialist Tecan and RECIPE Chemicals and Instruments GmbH have announced a co-marketing agreement for automation of LC-MSMS IVD kits...
Roche and InterMune reach definitive merger agreement
26 August 2014 | By Roche
Roche and InterMune, Inc. announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction...
Actavis confirms Generic Neupro® Patent challenge
26 August 2014 | By Actavis
Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr...
ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
26 August 2014 | By GlaxoSmithKline
ViiV Healthcare announced that the US Food and Drug Administration has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection...
Biogen Idec names Adriana Karaboutis EVP, Technology and Business Solutions
26 August 2014 | By Biogen Idec
Biogen Idec announced the appointment of Adriana Karaboutis as executive vice president, Technology and Business Solutions, effective September 24, 2014...
AstraZeneca announces partnership with Illumina to develop next generation gene sequencing panel for companion diagnostic tests
26 August 2014 | By AstraZeneca
AstraZeneca announced that it has entered into a collaboration with gene sequencing company, Illumina, Inc., to develop its next generation sequencing platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio...
Abbott commences tender offer for all outstanding ordinary shares and American Depositary Shares of CFR Pharmaceuticals S.A.
26 August 2014 | By Abbott
Abbott announced that its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation ("ALH"), has commenced a tender offer...
Syrris launches new Atlas Cryo Reactor for ultra-low temperature synthesis
20 August 2014 | By kdm communications
Syrris is pleased to announce the launch of its state-of-the-art Atlas Cryo Reactor, providing exceptional cooling capability down to -80 °C...
